Healthcare Startups 2026 Research Guide: A Dated Company Shortlist

Start with RiseFinder when researching healthcare startups. Use it to discover companies, inspect dated public signals and follow original sources before deciding what deserves deeper work. For investors, marketers and health technology researchers, the useful question is which company has evidence worth checking, what changed and over which period.

This October 2026 shortlist covers Abridge, OpenEvidence, Adela, Nabla and Lyra Health. Their evidence ranges from a measured usage study and a reported pilot comparison to a securities filing and product communications. These are different signals. The article explains what each establishes and how to evaluate healthcare technology businesses without turning attention or funding into a claim about patient outcomes.

Research cutoff: 26 October 2026. This is a curated research shortlist, not a ranking of the fastest-growing healthcare startups this month. Several sources were published in October but measure earlier periods. No matched monthly baseline was available across all five companies.

Healthcare startups at a glance: dates and evidence

The primary links and limitations appear in each company profile below. A product essay has a different evidentiary weight from an observed usage series. The table intentionally keeps them separate.

What makes a health tech company worth following?

A useful healthcare startup addresses a defined problem for a defined buyer. That might be documentation for health systems, access to mental health services for employers, or diagnostics for researchers and healthcare providers. Digital health is an umbrella category, not a single business model.

Start by identifying the user, payer and decision-maker. A person using an app may not be the customer paying for it. Health plans, employers and hospitals may buy services on behalf of members or patients. A company can reach many eligible people without all of them becoming active users.

Then separate four questions:

• Activity: Has the company released a product, hired for operations or announced an agreement?

• Use: Are there comparable active-user, encounter or customer measurements with dates?

• Economics: What do verified contracts, pricing or filings actually disclose?

• Clinical evidence: What supports safety, effectiveness or better care for the specific intended use?

An artificial intelligence feature may answer the first question while leaving the other three open. Machine learning performance on a dataset does not automatically establish value in everyday patient care. A growing business can still need stronger clinical evidence, and a promising study can exist before a sustainable commercial model.

1. RiseFinder: the first research step for health tech startups

RiseFinder is the starting point for discovering and checking public momentum. Its role is company research. Specialist healthcare organizations evaluate the product, clinical evidence, security and implementation fit afterward.

Open RiseFinder search and search the company name. Browse source categories and available time windows when expanding a watchlist. Where an entity has history, compare the earlier and latest readings, retain their observation dates and open the source link. Save useful candidates in your saved list, then read the methodology to understand what a signal measures.

For health tech research, keep a simple evidence ledger alongside that discovery work: legal identity, product, buyer, source, publication date, measurement period, actual metric and unanswered question. If there is no comparable baseline, write “not measured.” Missing data cannot support a zero-to-something growth calculation.

The companies below are an editorial shortlist checked against primary sources. Inclusion does not mean each has a currently published RiseFinder growth row or that RiseFinder has verified clinical claims. This distinction lets researchers use discovery signals without confusing them with a medical assessment.

2. Abridge: an agreement backed by a scoped pilot comparison

Abridge sells artificial intelligence software for clinical documentation and related workflows. On 8 October 2026, the company announced an enterprise-wide agreement with University of Texas REAL Health AI. It describes a framework allowing UT institutions to access its platform while keeping local implementation decisions. An agreement establishing access is not the same as every eligible clinician actively using the product. Abridge announcement.

The same announcement reports that the UT pilot increased recording clinicians by 73% and monthly notes by 80% over the preceding 12 months. These are company-reported changes within that pilot. The release does not provide the two absolute counts or exact observation dates needed to reconstruct the percentages independently. They are not October-only growth or evidence of improved health outcomes.

The research question is concrete: how does a pilot become sustained use across health systems? Look for institution-level implementation updates, comparable usage denominators and the workload of maintaining the integration. For doctors, nurses and care teams, assess how draft documentation is reviewed and how exceptions enter existing operations.

An AI powered assistant can have a clear administrative mission without proving every broader promise about clinical quality. Abridge's reported pilot comparison supports follow-up on implementation and use; it does not settle the effect on treatment, costs or patient experience.

3. OpenEvidence: a new study with an older measurement window

OpenEvidence is a clinical information platform using artificial intelligence to answer clinicians' questions. A JAMA cross-sectional study published on 15 October 2026 examined accounts verified through National Provider Identifiers from 1 January 2024 through 30 June 2026. It reports monthly active users increasing from 355 in January 2024 to 703,265 in June 2026. Original JAMA study.

That is a measured platform usage comparison, not a count of patients, paying customers or October users. Publication in October does not move the endpoint into October. The result supports research into demand for clinical information tools, while the study's population and period define its scope.

Harvard Medical School's account says three co-authors were OpenEvidence employees; the company supplied the de-identified data but did not fund the study. It also says the effect on clinical care remains a next research question. Those disclosures belong alongside the growth reading. Harvard Medical School research report.

For healthcare organizations, the next step is to examine source traceability, intended users, institutional access and how physicians verify answers. Frequent use of artificial intelligence does not establish accurate answers for every specialty, appropriate medications or improved patient outcomes. The right insights must be assessed in their clinical setting.

4. Adela: a precisely identified biotechnology filing

Adela develops blood-based cancer detection and monitoring technology using methylome analysis. Its official website describes that operating activity. The site's privacy policy identifies Adela, Inc., at 353 Hatch Drive, Foster City, California 94404, matching the issuer name and business address in the filing reviewed here. Adela product description, legal identity and address.

Adela's SEC Form D, accession 0001852167-26-000002, was filed on 19 October 2026. It reports a first sale on 2 October 2026, total offering amount of US$12 million, amount sold of US$12 million and zero remaining in that offering. The appropriate research signal is US$12 million of securities sold in this disclosed offering at the filing date. Exact SEC filing.

This filing is not a confirmed total funding round across all instruments, company revenue, cash balance or evidence of commercial adoption. It supplies no monthly clinical performance comparison. Funding activity and diagnostic validation require separate research.

For this company, follow the intended test use, study design, publication record and applicable regulatory status. Do not assume that a laboratory credential or financing filing establishes authorization or effectiveness for every cancer application. Adela belongs at the overlap of healthcare and biotechnology, rather than in a list of interchangeable telehealth services.

5. Nabla: current product direction, with a lower evidence weight

Nabla offers ambient AI documentation, dictation and coding tools. Its 22 October 2026 product essay discusses how encounter documentation relates to coding specificity. The page identifies the author as the company's chief clinical product officer. Nabla product essay.

This is useful evidence of the company's current product focus and messaging. It is not a measured growth series, independent trial or customer count. The author describes workflow experience; those observations should remain attributed rather than becoming universal claims about documentation accuracy or reimbursement.

The follow-up question is whether healthcare providers can see the relevant source context, review the draft and resolve errors within their existing workflow. Ask for a demonstration using approved synthetic examples, an implementation plan and evidence specific to the relevant specialty. Do not upload clinical data during casual vendor research.

Nabla illustrates why health tech startups need more than a launch story to demonstrate durable use. A new kind of artificial intelligence interface may attract attention; repeat deployment and verified operational results answer different questions.

6. Lyra Health: mental health platform availability needs a denominator

Lyra supports employer mental health benefits through technology and service infrastructure. Its current manager coaching communication specifies availability beginning 1 October 2026 for eligible members across the United States, with global expansion planned for 2027. This is announced availability, not evidence that every eligible member enrolled. Lyra manager coaching description.

Keep the company identity precise. Lyra's site states that professional services are provided by licensed clinicians affiliated with independent professional practices; Lyra Health, Inc. supplies administrative, technology and related support. Lyra official company disclosure.

For a mental health platform, distinguish eligible lives, registered members, active participants and completed sessions. Each denominator answers a different business question. Buyers should also assess access to qualified providers, escalation arrangements, coverage, affordability and the division between coaching and clinical treatment.

Mental health technology can support mental well being without making all services equivalent. A wellness exercise, a coaching session and licensed treatment carry different expectations. Evaluate the actual service and evidence for the population concerned, rather than treating the mission of improving lives as a measured result.

Compare digital health categories before comparing companies

Health tech startups operate across several markets. Comparing them within the same job makes research more useful.

Digital health and clinical workflow

Documentation, scheduling, billing and interoperability tools support the healthcare system's operations. For artificial intelligence products, inspect human review, integration and auditability. Administrative time savings and clinical quality are separate outcomes; define both before comparing vendors.

Healthcare organizations may ask for economic value, but a sales presentation about actionable insights is only a starting point. Request the baseline, study period, number of sites and actual costs of implementation. That creates a clearer view of demand than a broad claim about transforming the world.

Mental health and digital therapeutics

Mental health companies can offer provider access, coaching, wellness content or digital therapeutics. Do not group them by the presence of an app alone. For a product claiming a therapeutic effect, check its intended use, supporting studies and applicable authorization.

For employers and health plans, ask what a member can actually access, who supplies the care and how outcomes are assessed. Personalized health insights should have a defined purpose, evidence and handling rules. They do not by themselves establish effective treatment.

Remote patient monitoring and medical devices

Remote patient monitoring involves collecting health information away from a conventional visit. Research the devices, connectivity, review workflow and response responsibilities. Whether a platform is device-agnostic says little about whether providers can easily connect a particular device or act on its readings.

Do not assume remote patient monitoring always reduces readmissions or costs. Those claims need evidence for the condition, population, comparator and service model. The FDA explains that software oversight depends on the function and risk, with some software outside device regulation and other functions subject to it. FDA device software overview.

Telehealth startups and hybrid care

Telehealth businesses deliver or support care across distance. A hybrid service can combine remote contact with in-person care, testing or other services. Examine geographic access, provider licensing, patient consent, technology, continuity and payment arrangements.

HHS advises assessing platform functions such as scheduling, consent, participant limits and costs. That helps researchers compare actual services instead of assuming the same model works everywhere in the world. Pandemic-era demand is historical context, not proof that every telehealth startup is growing today. HHS vendor selection guidance.

How to evaluate healthcare startups without mixing signals

Use a repeatable monthly process, even when the available evidence is not monthly:

1. Define the market. Choose one problem, buyer and geography. Separate health plans from health systems and consumer businesses from enterprise software.

2. Discover with RiseFinder. Search names, browse relevant source categories and save candidates. Retain the actual date and metric behind each public signal.

3. Confirm identity and status. Match the operating website, legal entity and product. Do not merge similarly named organizations or label acquired businesses as independent startups.

4. Classify the evidence. Label a company announcement, measured usage study, funding filing, research publication or editorial essay correctly.

5. Check the comparison. Record both readings and dates. Use equal units and comparable populations. If the source gives only percentages, retain that limitation.

6. Investigate practical adoption. Ask who implements the technology, who pays, who reviews errors and how services fit daily operations. Long procurement processes and integration work deserve attention in the research plan.

7. Separate claims about lives from business signals. Funding, hiring and website interest do not prove better clinical outcomes. Review evidence for each claim separately.

Keep repeated coverage of one announcement in one evidence bucket. A company release, a syndicated copy and a social post do not create three independent confirmations. A product's future roadmap is also different from functionality available today.

Broaden the search without importing stale market maps

These category examples can help expand a watchlist, but they are not additional October growth picks.

Biofourmis describes a remote monitoring platform combining devices, analytics and clinical workflows. Its product page discusses artificial intelligence and machine learning, but a vendor's broad platform description is not evidence that every implementation reduces hospital readmissions. Also distinguish the operating business from the Biofourmis Connect life sciences platform, which ActiGraph now identifies as part of its ecosystem. Biofourmis platform, ActiGraph Connect.

Athelas currently describes its focus as documentation, billing and clinic operations. That is more specific than a generic claim that artificial intelligence provides real-time clinical insights. Record which product and workflow the company actually offers before evaluating a claim. Athelas official site.

PlushCare offers online doctor visits through telemedicine, including non-emergency urgent care. It illustrates the distinction between a software company selling to institutions and a service connecting patients with clinicians. Verify the current service, location and eligibility rather than importing a global telehealth total. PlushCare urgent care.

Ro explicitly states that its services are for people located in the United States, with availability varying by service and state. A claim that Ro serves patients in more than 100 countries conflicts with those terms and should not be used in a current company comparison. Ro terms.

Bicycle Health provides a useful lesson about historical denominators: its description of a published treatment model says it had served more than 10,000 patients across 23 states at the time of that study. Those historical observations cannot establish today's patient count or geographic footprint. Do not reuse a smaller older patient total as a current growth baseline without the matching dates. Bicycle Health study description.

For mental health research, SonderMind describes provider matching and insurance-dependent therapy and psychiatry access, while Meru Health describes a program supported by licensed therapists. These represent different service designs. An old funding total does not describe current provider availability or a patient's insurance coverage. SonderMind coverage, Meru Health providers.

These examples show why a useful digital health market map needs current operating evidence. The company's mission, an artificial intelligence label and a cumulative funding figure cannot substitute for a clear description of what is available.

Digital health research in 2026: compare the buyer's job

A useful digital health market map separates clinical services, administrative software, workforce tools and consumer wellness. These health tech companies may all use artificial intelligence, but they sell different work to different buyers. Hospitals may buy documentation or billing software; health plans may buy a chronic care service; employers may buy a mental health platform. Investors and family offices should define that comparison group before reviewing company evidence.

For digital health investors, a transparent measurement is more useful than a speculative market headline. Record the business model, what the software does, who checks its output and whether a claimed benefit concerns operations, healthcare costs or health outcomes. Better health outcomes require evidence about patients, while a lower cost billing workflow needs an operational comparison. The same proof cannot answer both questions.

Clinical workflows, interoperability and artificial intelligence

The Abridge and OpenEvidence examples show why healthcare AI research increasingly concerns infrastructure inside clinical workflows. Medical professionals need access to relevant information, while healthcare organizations need software that works with medical records and existing systems. Evaluate data interoperability, source traceability, permissions and review responsibilities before accepting a promise of seamless integration.

Ask where data analytics supports a decision and where a person retains responsibility. Agentic AI can perform sequences of administrative tasks; it should not be assumed to have the same autonomy in clinical treatment. A next generation label does not establish regulatory readiness or safe handling of patient data. Read the intended use and validation record for the actual application.

A Bessemer Venture Partners and Bain survey published on 30 September 2026 surveyed 226 healthcare executives. It reported that semi- or fully autonomous agents were much more common among provider revenue cycle respondents than in clinical use cases. Those are survey responses from a defined executive sample, not an audit of every hospital or clinical outcomes trial. The distinction supports a practical question: where does automation remove manual work, and where is oversight still essential? Original survey report.

Billing and workforce technology: three different metrics

Inbox Health is a patient billing software company. Its 16 July 2025 announcement describes an AI billing assistant and reports serving more than 3,500 healthcare practices and 2.8 million patients a year. These are historical company-reported operating totals, not a current October 2026 growth measurement. Billing automation concerns revenue cycle management and the patient financial experience; it does not demonstrate improved medical treatment. Inbox Health's dated announcement.

Stepful provides healthcare training. Its company-owned college's current about page says Stepful has graduated more than 30,000 students since launch. A cumulative graduate count differs from current enrollment, a monthly active student count and job placement. Keep those data definitions separate when researching healthcare workforce technology. Stepful College company description.

Clasp connects education financing with healthcare recruitment. Its 9 July 2025 announcement reports participating employers offering a combined US$101.2 million-plus in student loan repayment commitments. That is an employer commitment measure, not venture funding raised by Clasp, cash already paid to students or a clinical result. The same release discusses a separate loan funding capacity; do not merge the two figures. Clasp's original announcement.

Carefam describes a career platform matching clinicians to healthcare roles and automating hiring work. The operating description helps identify the company, but a network size needs its own dated source and definition. A profile, a scheduled interview and a completed hire measure different stages of demand. Carefam official site.

Twin Health and Cadence: chronic care is a distinct category

Twin Health describes a digital twin model using sensor and smart-device data to provide individualized guidance about metabolic health. Its current site links that model with providers and coaches. This is a company description of its product and care model, not independent confirmation that every participant achieves better outcomes or can reduce medications. Twin Health official site.

For Twin Health and similar digital health services, ask how wearable readings, laboratory tests and other inputs inform guidance, what clinicians review and which study supports a particular claim. Chronic diseases and chronic conditions require defined populations and follow-up. A disease simulation or personalized prediction is different from a measured change in health outcomes.

Cadence describes clinical AI supporting chronic care between visits and currently states that it works with 20-plus health systems. That establishes the company's reported institutional reach on the page reviewed, not a dated active-patient count. Do not combine it with an older patient total without matching the observation date and population. Cadence official site.

Digital health can enable remote monitoring, primary care follow-up and hybrid virtual care alongside in-person services. Proactive wellness and prevention may help define a product's intended role in everyday life, but consumer interest, repeat use and clinical benefit each need evidence. Mobile phones and connected devices make delivery possible; they do not alone establish safe treatment or lower healthcare costs.

Put digital health funding figures in their original window

Rock Health's report published on 7 July 2025 records US$6.4 billion of venture funding for U.S.-based digital health companies in the first half of 2025. It assigns 62% to AI-enabled startups. Multiplying those reported figures gives about US$3.97 billion, or nearly US$4 billion, for that half-year AI-enabled group. This is an approximate calculation from rounded report figures, not a full-year global funding total or an audited sum of individual company filings. Rock Health's original H1 2025 report.

That historical digital health funding context can help explain investor attention to workflow software and data infrastructure. It cannot prove that a company is growing now, that millions of people actively use its product or that an announced funding round closed on every reported term. Check each company financing separately, as the Adela example demonstrates.

Keep geography and sector definitions together. In Partech's 2025 Africa tech venture equity data, fintech remained the largest sector at 32% of equity funding, while healthtech received US$215 million. This is a regional technology-sector comparison under that report's definitions, not U.S. digital health or global healthcare funding. Match countries, capital types and sector boundaries before comparing headlines or drawing conclusions about healthcare demand. Partech's original equity breakdown.

Market research should also distinguish payment incentives from clinical effects. For a digital health service pursuing value-based care, ask which population, quality measures, contracts and total-cost comparison apply. Automation may assist quality reporting or prior authorizations; it does not automatically produce better outcomes or reimbursement. Rising care costs and an aging population are questions for the market analysis, rather than evidence that any particular startup will succeed.

Use the same discipline when tech giants enter a category. A large software company's distribution, a startup's specialist focus and an incumbent healthcare provider's workflow access are different advantages. For healthcare industry research, assess the actual deployment and buyer requirements. This keeps the digital health watchlist tied to sustainable business questions instead of generalized enthusiasm for innovation.

Test the evidence behind digital health trends

Healthcare research in 2026 needs explicit checks for data security and regulatory compliance. Map what information enters the software, which organizations receive it, who can access it and how medical professionals review outputs. Do not infer protection from a general AI label. The FDA distinguishes digital health functions spanning general wellness, personalized medicine and medical devices; the actual function determines which regulatory questions apply. FDA digital health overview.

There is research behind the effort to reduce documentation burden. A Stanford prospective quality improvement study published in the February 2025 journal issue evaluated ambient scribes with 48 physicians over three months. Paired surveys reported lower burden and burnout. This was a specific implementation and survey design, not proof that every ambient product prevents burnout or improves patient outcomes. Original study abstract.

Decentralized care can move monitoring and contact outside hospitals while retaining a clinical team. Cadence's 10 December 2025 company report described 74,000 patients cared for and 21 health-system partners. The same release reports 23.3 million vitals transmitted in 2025, described as nearly triple 2024. This company-reported activity illustrates expansion of connected remote care, with the 2025 figure reported as of the December release. These historical operating totals provide a dated reference, rather than a current October 2026 patient count. They do not establish universal clinical effectiveness. Cadence's dated report announcement.

The pandemic did accelerate telehealth usage in a measured historical sample. CDC analyzed encounters from four large U.S. telehealth providers and reported a 154% increase in the last week of March 2020 versus the same period in 2019. That comparison supports historical context; current digital health demand requires newer observations. CDC's original analysis.

Revenue cycle software is one administrative area attracting investor attention in the Bessemer and Bain report above. It remains important to distinguish patient billing, insurance claims, coding and reimbursement. A useful research comparison identifies the actual task before asking whether automation improves it.

AI also supports a different part of healthcare: drug development. Chai Discovery describes molecular design models, and its technical work discusses predicted structures and experimental testing of designed antibodies. This is research toward candidate discovery, not a clinical demonstration that a medicine treats disease. Chai's dated technical report.

Frequently asked questions

Which healthcare startups are growing fastest?

This shortlist cannot establish a whole-market winner. OpenEvidence has a dated usage comparison; Abridge reports changes within a particular pilot. Adela's filing and the other product communications measure different things. A defensible ranking requires comparable metrics, populations and observation dates for the companies included.

What is a digital health company?

It is a company using technology to support health-related information, services or workflows. The category includes clinical software, remote care and some medical devices. Determine the specific intended use before assessing evidence, buyers or regulation. “AI powered” describes an implementation approach, not a clinical result.

Is Flatiron Health still an independent startup?

Roche completed its acquisition of Flatiron Health in April 2018 and describes it as an independent affiliate within the Roche Group. Flatiron Health remains relevant to oncology technology research, but it should not be silently grouped with independently owned early-stage healthcare startups. Roche company profile.

Does a funding announcement prove healthcare traction?

No. A funding announcement describes financing on its stated terms. A Form D discloses information about a specific securities offering. Neither automatically measures product use, reimbursement, commercial revenue or clinical effectiveness. Check the legal entity and exact document before quoting an amount; do not infer a Series B label from a filing that does not state it.

Where else can researchers find health tech startups?

Accelerators, industry communities, clinical publications and company websites can supply candidates. A Y Combinator directory entry, a San Francisco office or conference participation can help identify a business, but each needs a separate reason for inclusion in a growth analysis. Geography and accelerator membership do not establish scale, quality or a unique solution.

What should an AI healthcare evaluation focus on?

Define the task, users and risk first. For artificial intelligence and machine learning tools, ask how outputs are checked, what happens when the system fails, how data is handled and which evaluation matches the use case. No single product can be the only solution for every healthcare problem. The goal is better decisions about a defined workflow, supported by evidence.

Build a healthcare watchlist you can revisit

Start with RiseFinder to discover candidates and inspect dated public evidence. Save a small watchlist, keep source links and compare the same measurements when new observations appear. Then investigate the company, clinical evidence and implementation requirements appropriate to its category.

That process gives investors and content teams a useful next action: follow a specific signal, test a specific question and update the record when stronger evidence arrives.